These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 23796137)

  • 1. Glycogen synthase kinase 3 substrates in mood disorders and schizophrenia.
    Cole AR
    FEBS J; 2013 Nov; 280(21):5213-27. PubMed ID: 23796137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is glycogen synthase kinase-3 a central modulator in mood regulation?
    Li X; Jope RS
    Neuropsychopharmacology; 2010 Oct; 35(11):2143-54. PubMed ID: 20668436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs.
    Gould TD; Manji HK
    Neuropsychopharmacology; 2005 Jul; 30(7):1223-37. PubMed ID: 15827567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Role of glycogen synthase kinase-3β in the pathogenesis of mental disorders].
    Ivanova SA; Losenkov IS; Bokhan NA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(6):93-100. PubMed ID: 25075421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders.
    Gould TD; Picchini AM; Einat H; Manji HK
    Curr Drug Targets; 2006 Nov; 7(11):1399-409. PubMed ID: 17100580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting glycogen synthase kinase-3 as an approach to develop novel mood-stabilising medications.
    Gould TD
    Expert Opin Ther Targets; 2006 Jun; 10(3):377-92. PubMed ID: 16706678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions.
    Jope RS; Roh MS
    Curr Drug Targets; 2006 Nov; 7(11):1421-34. PubMed ID: 17100582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An emerging role for Wnt and GSK3 signaling pathways in schizophrenia.
    Singh KK
    Clin Genet; 2013 Jun; 83(6):511-7. PubMed ID: 23379509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease.
    Gao C; Hölscher C; Liu Y; Li L
    Rev Neurosci; 2011 Dec; 23(1):1-11. PubMed ID: 22718609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycogen synthase kinase 3: a drug target for CNS therapies.
    Bhat RV; Budd Haeberlein SL; Avila J
    J Neurochem; 2004 Jun; 89(6):1313-7. PubMed ID: 15189333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute selective glycogen synthase kinase-3 inhibition enhances insulin signaling in prediabetic insulin-resistant rat skeletal muscle.
    Dokken BB; Sloniger JA; Henriksen EJ
    Am J Physiol Endocrinol Metab; 2005 Jun; 288(6):E1188-94. PubMed ID: 15671078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycogen synthase kinase-3: The missing link to aberrant circuit function in disorders of cognitive dysfunction?
    Manduca JD; Thériault RK; Perreault ML
    Pharmacol Res; 2020 Jul; 157():104819. PubMed ID: 32305493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of mouse brain glycogen synthase kinase-3 by atypical antipsychotics.
    Li X; Rosborough KM; Friedman AB; Zhu W; Roth KA
    Int J Neuropsychopharmacol; 2007 Feb; 10(1):7-19. PubMed ID: 16672106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The common inositol-reversible effect of mood stabilizers on neurons does not involve GSK3 inhibition, myo-inositol-1-phosphate synthase or the sodium-dependent myo-inositol transporters.
    Di Daniel E; Cheng L; Maycox PR; Mudge AW
    Mol Cell Neurosci; 2006; 32(1-2):27-36. PubMed ID: 16531065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: therapeutic implications.
    Manji HK; Bebchuk JM; Moore GJ; Glitz D; Hasanat KA; Chen G
    J Clin Psychiatry; 1999; 60 Suppl 2():27-39; discussion 40-1, 113-6. PubMed ID: 10073385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Akt/GSK3 signaling in the action of psychotropic drugs.
    Beaulieu JM; Gainetdinov RR; Caron MG
    Annu Rev Pharmacol Toxicol; 2009; 49():327-47. PubMed ID: 18928402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of glycogen synthase kinase 3 in squamous differentiation induced by cigarette smoke in porcine tracheobronchial epithelial cells.
    Tian D; Zhu M; Chen WS; Li JS; Wu RL; Wang X
    Food Chem Toxicol; 2006 Sep; 44(9):1590-6. PubMed ID: 16750592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperactivity: glycogen synthase kinase-3 as a therapeutic target.
    Mines MA
    Eur J Pharmacol; 2013 May; 708(1-3):56-9. PubMed ID: 23500205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycogen synthase kinase 3 (GSK3) in the heart: a point of integration in hypertrophic signalling and a therapeutic target? A critical analysis.
    Sugden PH; Fuller SJ; Weiss SC; Clerk A
    Br J Pharmacol; 2008 Mar; 153 Suppl 1(Suppl 1):S137-53. PubMed ID: 18204489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors of Glycogen Synthase Kinase 3 with Exquisite Kinome-Wide Selectivity and Their Functional Effects.
    Wagner FF; Bishop JA; Gale JP; Shi X; Walk M; Ketterman J; Patnaik D; Barker D; Walpita D; Campbell AJ; Nguyen S; Lewis M; Ross L; Weïwer M; An WF; Germain AR; Nag PP; Metkar S; Kaya T; Dandapani S; Olson DE; Barbe AL; Lazzaro F; Sacher JR; Cheah JH; Fei D; Perez J; Munoz B; Palmer M; Stegmaier K; Schreiber SL; Scolnick E; Zhang YL; Haggarty SJ; Holson EB; Pan JQ
    ACS Chem Biol; 2016 Jul; 11(7):1952-63. PubMed ID: 27128528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.